Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Up 5.3% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics, Inc. (NTLA) is a biotechnology company specializing in developing CRISPR/Cas9-based therapies for genetic diseases and witnessed a strong bullish movement in the market.

Why is Intellia Therapeutics, Inc. going up?

NTLA stock is up 5.3% on Mar 25, 2026 16:55

• The rise in NTLA's stock price might be due to positive sentiment from AI models suggesting short-term strength and the adoption of potential institutional trading strategies.
• Despite recent selling by Hudson Bay Capital Management LP and company insiders, the stock surpassed Q3 revenue and EPS estimates, indicating solid fundamentals.
• A possible securities class action lawsuit alleging lack of disclosure on the inefficiency of the NTLA-3001 program initially led to a stock price decline, but investors appear hopeful about the company's future prospects.
• In summary, the surge in Intellia Therapeutics' stock price today could be driven by a blend of positive sentiment, exceeding financial expectations, and potential institutional trading strategies.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

Investors in Intellia Therapeutics, Inc. Should Contact Levi & Ko

Levi & Korsinsky LLP is urging investors in Intellia Therapeutics, Inc. (NASDAQ: NTLA) who suffered losses between July 30, 2024, and January 8, 2025, to contact them regarding a potential securities class action lawsuit. The lawsuit alleges that Intellia failed to disclose that its NTLA-3001 program was becoming inefficient due to the rise of non-viral delivery methods, leading to a significant stock drop after the company announced a reorganization and workforce reduction. Investors have until April 14, 2025, to discuss their rights.

https://natlawreview.com/press-releases/investors-intellia-therapeutics-inc-should-contact-levi-korsinsky-april-14

Hudson Bay Capital Management LP Sells 235,000 Shares of Intellia Therapeutics, Inc. $NTLA

Hudson Bay Capital Management LP significantly reduced its stake in Intellia Therapeutics (NASDAQ:NTLA) by 50.5%, selling 235,000 shares and retaining 230,000 shares valued at approximately $3.97 million. Company insiders also sold over 53,000 shares in the last 90 days. Despite the institutional sell-off, Intellia Therapeutics exceeded Q3 revenue and EPS estimates, though it remains unprofitable, with analysts holding a consensus "Hold" rating and an average price target of $19.59.

https://www.marketbeat.com/instant-alerts/filing-hudson-bay-capital-management-lp-sells-235000-shares-of-intellia-therapeutics-inc-ntla-2026-03-22/

How Intellia Therapeutics Inc. (NTLA) Affects Rotational Strategy Timing

The article analyzes Intellia Therapeutics Inc. (NTLA) using AI models, identifying a positive near-term sentiment while a mid-term weak bias exists within a long-term strength context. It highlights an exceptional 112.5:1 risk-reward short setup and provides institutional trading strategies for various risk profiles, including position trading, momentum breakout, and risk hedging. Multi-timeframe signal analysis offers insights into support and resistance levels across different horizons.

https://news.stocktradersdaily.com/news_release/15/How_Intellia_Therapeutics_Inc._NTLA_Affects_Rotational_Strategy_Timing_032026021802_1774030682.html

Trending Today

Coinbase Global Inc. ($COIN) Stock Forecast: Down 5.3% Today

Gartner Inc. ($IT) Stock Forecast: Up 5.2% Today

Pinterest Inc. Class A ($PINS) Stock Forecast: Down 3.0% Today

Gasoline ($GASOLINE) Commodity Forecast: Up 5.7% Today

Brent Crude Oil ($BRENT) Commodity Forecast: Up 6.4% Today

Crude Oil ($CRUDE) Commodity Forecast: Up 5.0% Today

Corning Incorporated ($GLW) Stock Forecast: Down 6.1% Today

Harley-Davidson Inc. ($HOG) Stock Forecast: Up 5.8% Today

Baxter International Inc. ($BAX) Stock Forecast: Up 5.1% Today

Super Micro Computer Inc ($SMCI) Stock Forecast: Down 5.5% Today

Intellia Therapeutics, Inc. Price History

26.01.2026 - NTLA Stock was up 10.7%

• After revealing its Q4 earnings, NTLA stock saw a noteworthy increase in value, surprising analysts who had forecast a marginal decrease in both EPS and revenue compared to the previous year.
• The FDA's decision to remove a clinical hold on Intellia's gene-editing medication had a favorable impact on the stock's performance, hinting at potential competitiveness in the rare disease pharmaceuticals market.
• Intellia's upcoming involvement in investor conferences scheduled for March 2026 also played a role in boosting market confidence, as investors displayed keen interest in the company's strategic vision and growth prospects.

05.02.2026 - NTLA Stock was down 5.1%

• The bearish movement in NTLA stock today could be attributed to profit-taking by investors after a recent surge in the stock price.
• Actions impacting GLP-1 compounders by the FDA might have raised concerns about regulatory scrutiny in the biotech sector, negatively affecting NTLA's stock.
• Despite positive clinical news and increased stake by Vanguard Group Inc., the overall market sentiment towards biotech companies like Intellia might have been affected by the uncertainty surrounding FDA actions and regulatory compliance.
• Insider sales at Intellia, the company's pre-revenue status, and negative margins could have also contributed to the bearish sentiment among investors.

05.02.2026 - NTLA Stock was down 5.1%

• Despite recent positive developments, such as analyst upgrades, strong financial results, and progress with its Phase 3 trial after regulatory hurdles were resolved, Intellia Therapeutics saw a decline in its stock price.
• The market response may have been influenced by the company's decision to expand its At-The-Market offering program to $1.04 billion, which could potentially lead to dilution of existing shares and impact shareholder value.
• Concerns regarding the company's financial performance, such as negative margins and a high valuation, despite advancements in its pipeline and clinical work, might have unsettled investors.
• The divergence in opinions among analysts and the uncertainty surrounding Intellia's path to profitability likely contributed to the negative market sentiment, even amidst positive strides in its therapeutic initiatives.

03.02.2026 - NTLA Stock was down 5.1%

• The stock price of Intellia Therapeutics plummeted despite recent positive developments and analyst upgrades, indicating a possible case of "buy the rumor, sell the news" behavior among investors.
• The FDA's decision to lift the clinical hold on the MAGNITUDE Phase 3 trial for a key therapy was initially seen as a positive development, but concerns over the safety and efficacy of the treatment may have led to the market's negative reaction.
• The company's decision to increase its At-The-Market offering program to $1.04 billion could have also contributed to the bearish sentiment, signaling potential dilution of existing shares and impacting shareholder value.
• Overall, the market movement suggests that investors may be exercising caution and reevaluating their positions in Intellia Therapeutics amidst a mix of positive news and financial decisions by the company.

24.01.2026 - NTLA Stock was up 5.7%

• The development of an investigational gene editing therapy for hereditary transthyretin (ATTR) amyloidosis through CRISPR/Cas9 technology has likely spurred investor optimism and interest in Intellia Therapeutics.
• Encouraging reduction in harmful protein production observed in early clinical trial findings could pave the way for advancements in treating genetic disorders, potentially enhancing the company's standing and stock performance.
• Noteworthy institutional investments, such as those from Jupiter Asset Management Ltd. amounting to $23.52 million, signal increasing confidence in Intellia Therapeutics' future prospects and may have influenced the recent positive market trend.
• Anticipation surrounding an imminent conference call to discuss financial results and business updates could be fueling positive investor sentiment and driving up the stock price.

19.02.2026 - NTLA Stock was down 5.4%

• Farallon Capital Management LLC acquired a significant number of shares in NTLA, indicating confidence in the company's potential.
• Despite reporting better-than-expected earnings and surpassing analyst revenue estimates, company insiders have been selling shares in the last ninety days.
• The increased holdings by institutional investors may have contributed to the downward pressure on NTLA's stock price.
• The bearish movement could be a result of profit-taking by insiders or concerns about the sustainability of NTLA's recent positive performance.

19.01.2026 - NTLA Stock was up 6.3%

• The bullish movement in NTLA stock today is linked to the lifting of the clinical hold on the MAGNITUDE-2 study, enabling expanded enrollment and updated safety protocols.
• The scheduled conference call to discuss fourth-quarter and full-year 2025 financial results and business updates likely impacted investor confidence in the company's future.
• H.C. Wainwright's increased price target and reiterated Buy rating contributed to a positive investor sentiment towards Intellia Therapeutics.
• Investor optimism about Intellia's gene-editing platform has been bolstered by regulatory clearance and the company's safety improvement efforts, driving the bullish market movement.

25.02.2026 - NTLA Stock was up 5.3%

• The rise in NTLA's stock price might be due to positive sentiment from AI models suggesting short-term strength and the adoption of potential institutional trading strategies.
• Despite recent selling by Hudson Bay Capital Management LP and company insiders, the stock surpassed Q3 revenue and EPS estimates, indicating solid fundamentals.
• A possible securities class action lawsuit alleging lack of disclosure on the inefficiency of the NTLA-3001 program initially led to a stock price decline, but investors appear hopeful about the company's future prospects.
• In summary, the surge in Intellia Therapeutics' stock price today could be driven by a blend of positive sentiment, exceeding financial expectations, and potential institutional trading strategies.

18.01.2026 - NTLA Stock was up 5.1%

• The surge in NTLA stock can be linked to the regulatory approval to resume the MAGNITUDE-2 study with expanded enrollment and enhanced safety protocols.
• Analysts, including H.C. Wainwright, have raised price targets and reiterated Buy ratings on NTLA, showing increased confidence in the company's gene-editing technology.
• Investors are focusing on the trial progress, safety updates, and Intellia's path to profitability amid industry competition despite regulatory advancements.
• The decision to lift the clinical hold marks a significant milestone for Intellia, potentially altering its risk profile and impacting future pricing discussions and partnership opportunities.

27.01.2026 - NTLA Stock was up 5.2%

• Intellia Therapeutics (NTLA) reported a Q4 loss of $0.83 per share, but exceeded revenue estimates, indicating strong potential for revenue growth.
• The positive momentum was driven by an earnings beat, promising trial data for hereditary angioedema, and the release of an FDA clinical hold, boosting investor confidence in the company's pipeline.
• The stock's valuation narrative is mixed, with discussions about high current multiples but substantial undervaluation based on future revenue potential, emphasizing the significance of upcoming milestones such as the Phase 3 HAELO trial for future growth.
• Despite recent share price increases, the company's three-year return is negative, signaling investor optimism about Intellia Therapeutics' long-term prospects despite some short-term obstacles.

02.02.2026 - NTLA Stock was up 5.6%

• Intellia Therapeutics observed a significant uptrend in trading today, driven by a variety of positive developments:
• The company posted strong Q4 2025 earnings and revenue, surpassing expectations and demonstrating robust financial performance.
• Analysts at Chardan Capital reiterated a "Buy" rating with a target price of $26, showcasing confidence in the company's growth trajectory.
• Investor optimism has been fueled by Intellia's focus on its lonvo-z candidate for HAE, with upcoming Phase 3 data and a BLA submission.
• The FDA's removal of the clinical hold on Intellia's MAGNITUDE-2 trial for its gene-editing programs has further bolstered positive sentiment surrounding the stock.

11.02.2026 - NTLA Stock was down 7.9%

• Despite promising long-term data for its HAE candidate and FDA approval for its ATTR-CM therapy, concerns persist among investors regarding ongoing losses, liver safety issues, and lengthy path to profitability.
• The participation in the Leerink Global Healthcare Conference could give the company a chance to address investor worries and clarify its strategic outlook.
• The stock price surge following the FDA's removal of clinical holds on its gene-editing drug nex-z reflects investor confidence, although safety concerns and high costs of gene-editing therapies remain.
• NTLA is deemed undervalued compared to its fair value estimate, indicating that investors, despite recent positive developments, are still wary of potential clinical hurdles or slow therapy adoption that could impact future performance.